Liu Yan-Wen, Du Ying, Chen Bao-An
Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu Province, China.
J Int Med Res. 2019 Dec;47(12):5926-5936. doi: 10.1177/0300060519882545. Epub 2019 Nov 19.
To determine the effectiveness and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer and peritoneal metastases.
PubMed®, CNKI, Web of Science, VIP and WANFANG databases were searched to identify randomized controlled trials (RCTs) that examined the effect of HIPEC on survival, clinical response and adverse events. Patients with advanced gastric cancer and peritoneal metastases were divided into an experimental group and a control group. The statistical results are presented as relative ratio (RR), mean difference (MD) and 95% confidence interval (CI).
Twenty-one RCTs met the inclusion criteria ( = 1674 patients). Meta-analysis showed that the 3-year survival rate was significantly higher in the HIPEC group than in the control group (RR 1.61; 95% CI 1.43, 1.82) and the complete response rate was significantly higher in the HIPEC group than in the control group (RR 2.35; 95% CI 1.67, 3.31). HIPEC was also beneficial in terms of decreased CEA (MD −1.79; 95% CI −2.22, −1.35). There was no significant difference in the rate of adverse reactions (RR 1.00; 95% CI 0.87, 1.14).
HIPEC had a beneficial effect on 3-year survival rate and complete response in patients with advanced gastric cancer and peritoneal metastases.
确定热灌注腹腔化疗（HIPEC）对晚期胃癌伴腹膜转移患者的有效性和安全性。
检索PubMed®、中国知网、Web of Science、维普和万方数据库，以识别研究HIPEC对生存、临床反应和不良事件影响的随机对照试验（RCT）。将晚期胃癌伴腹膜转移患者分为实验组和对照组。统计结果以相对比值（RR）、平均差值（MD）和95%置信区间（CI）表示。
21项RCT符合纳入标准（n = 1674例患者）。荟萃分析显示，HIPEC组的3年生存率显著高于对照组（RR 1.61；95% CI 1.43，1.82），且HIPEC组的完全缓解率显著高于对照组（RR 2.35；95% CI 1.67，3.31）。HIPEC在降低癌胚抗原方面也有益（MD −1.79；95% CI −2.22，−1.35）。不良反应发生率无显著差异（RR 1.00；95% CI 0.87，1.14）。
HIPEC对晚期胃癌伴腹膜转移患者的3年生存率和完全缓解有有益影响。
